X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will advance research and development and clinical trial expenses of company's pipeline including LP352 (bexicaserin), an oral, centrally acting, 5-HT2C superagonist for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $241.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 08, 2024
Details:
The net proceeds will advance research and development expenses, clinical trial expenses of company's pipeline including LP352, an oral, centrally acting, 5-HT2C superagonist in development for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
The net proceeds will advance research and development expenses, clinical trial expenses of company's pipeline including LP352, an oral, centrally acting, 5-HT2C superagonist in development for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 02, 2024
Details:
LP352 (Bexicaserin) is a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist, which is under phase 1/2 clinical development for the treatment of Developmental and Epileptic Encephalopathies (DEEs).
Lead Product(s): Bexicaserin
Therapeutic Area: Rare Diseases and Disorders Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
LP352 (Bexicaserin) is a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist, which is under phase 1/2 clinical development for the treatment of Developmental and Epileptic Encephalopathies (DEEs).
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
LP659 is a S1P1/5 receptor Modulator, small molecule drug, which is currently being investigated for the treatment of rare neuroinflammatory conditions.
Lead Product(s): LP659
Therapeutic Area: Rare Diseases and Disorders Product Name: LP659
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
LP352 is an oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with DEEs such as Lennox-Gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other epileptic disorders.
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
The agreement spans a range of Societal CDMO’s offerings including technology transfer and analytical method validation activities to support Longboard’s Oral, Centrally Acting 5-HT2C Receptor Superagonist, LP352, being developed for treatment of refractory seizures.
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Societal CDMO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, including LP352 and for working capital and other general corporate purposes.
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evercore ISI
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 10, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of LP352, and supporting business development activities, and for general corporate purposes.
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evercore ISI
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
